We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

SYSMEX-EUROPA

Sysmex Europe designs and produces laboratory and hematology diagnostic solutions, including instruments, reagents, c... read more Featured Products: More products

Download Mobile App




Automated Immunoassay Systems Evaluated for KL‐6 Antigen Quantification

By LabMedica International staff writers
Posted on 20 Nov 2019
Print article
Image: The HISCL-5000 is a fully automated immunoassay analyzer with a throughput of 200 tests per hour. The incubation time for each parameter is 17 minute and allows each laboratory to achieve maximum efficiency and productivity (Photo courtesy of Sysmex Corporation).
Image: The HISCL-5000 is a fully automated immunoassay analyzer with a throughput of 200 tests per hour. The incubation time for each parameter is 17 minute and allows each laboratory to achieve maximum efficiency and productivity (Photo courtesy of Sysmex Corporation).
Interstitial lung disease (ILD) is a group of diseases characterized by various forms of pulmonary interstitial inflammation and fibrosis, which are usually chronic, progressive, and fatal, causing death 2‐5 years after diagnosis in most patients.

The sputum saccharide chain antigen, Krebs von den Lungen‐6 (KL‐6), is a serum biomarker of lung injury. Since the most important feature of ILD is repeated damage or repair of type II alveolar epithelial cells, KL‐6 is secreted by these cells, and therefore KL‐6 is considered the most accurate biomarker in the diagnosis of ILD.

Immunologists at The First Affiliated Hospital of Guangzhou Medical University (Guangzhou, China) and their associates collected serum samples from 145 individuals between May 2018 and October 2018. Of 145 subjects, 25 had lung cancer, 56 had ILD, 35 had other respiratory diseases, and 29 were healthy individuals (control group) who underwent regular health checkup. There were 83 (57.24%) men and 62 women with a median age distribution of 56 years (interquartile range: 46-67).

The scientists evaluated the basic performance of KL‐6 assays using the HISCL‐5000 analyzer (Sysmex Corporation, Kobe, Japan), a fully automated immunochemistry analyzer that employs a chemiluminescence enzyme immunoassay (CLEIA) methodology with a two‐step sandwich immunoassay. The results were compared with those from the LUMIPULSE G1200 analyzer (Fujirebio Europe N.V., Zwijnaarde, Belgium). The analytical measurement ranges of HISCL‐5000 and LUMIPULSE G1200 were 10‐6,000 U/mL and 50‐10,000 U/mL, respectively.

The scientists reported that with a cutoff level of 500 U/mL, comparing the two systems, the agreement, sensitivity, specificity, and kappa value were 99.2%, 100%, 98.63%, and 0.984, respectively. Spearman's correlation and intraclass correlation coefficient (ICC) showed that there was a strong correlation between serum KL‐6 levels measured by the two systems. The clinical diagnosis agreement rate in both systems was >80%. The KL‐6 level in the ILD group was significantly higher than that in the non‐ILD groups, and the KL‐6 level (1,558, 726‐2,772.5) in the ILD group detected by HISCL‐5000 was significantly higher than that in the lung cancer group (339, 207‐424), other respiratory disease group (249, 194‐366), and control group (198, 131.5‐297).

The authors concluded that the HISCL‐5000 CLEIA system has a high diagnostic efficiency. The method can be applied to the quantitative detection of serum KL‐6 in patients with respiratory diseases. Compared with those in other respiratory diseases, the serum KL‐6 level in patients with ILD is significantly increased, suggesting that clinicians can use KL‐6 in the auxiliary diagnosis of ILD. The study was published on November 6, 2019 in the Journal of Clinical Laboratory Analysis.

Related Links:
The First Affiliated Hospital of Guangzhou Medical University
Sysmex Corporation
Fujirebio Europe N.V.


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.